News
AGYTF
0.159
NaN%
--
Weekly Report: what happened at AGYTF last week (0609-0613)?
Weekly Report · 3d ago
Allergy Therapeutics Unveils Promising Research at EAACI 2025
TipRanks · 6d ago
Allergy Therapeutics and EAACI Honor Early Career Researcher
TipRanks · 06/10 06:21
Weekly Report: what happened at AGYTF last week (0602-0606)?
Weekly Report · 06/09 10:49
Weekly Report: what happened at AGYTF last week (0526-0530)?
Weekly Report · 06/02 10:56
Weekly Report: what happened at AGYTF last week (0519-0523)?
Weekly Report · 05/26 10:56
Weekly Report: what happened at AGYTF last week (0512-0516)?
Weekly Report · 05/19 10:48
Weekly Report: what happened at AGYTF last week (0505-0509)?
Weekly Report · 05/12 10:49
Weekly Report: what happened at AGYTF last week (0428-0502)?
Weekly Report · 05/05 10:50
Weekly Report: what happened at AGYTF last week (0421-0425)?
Weekly Report · 04/28 10:58
Weekly Report: what happened at AGYTF last week (0414-0418)?
Weekly Report · 04/21 10:58
Weekly Report: what happened at AGYTF last week (0407-0411)?
Weekly Report · 04/14 10:49
Weekly Report: what happened at AGYTF last week (0331-0404)?
Weekly Report · 04/07 10:48
Weekly Report: what happened at AGYTF last week (0324-0328)?
Weekly Report · 03/31 10:58
Allergy Therapeutics Reports Financial Turnaround and Clinical Progress
TipRanks · 03/31 06:12
Allergy Therapeutics Advances Peanut Allergy Vaccine Trial to Final Phase
TipRanks · 03/27 07:16
Weekly Report: what happened at AGYTF last week (0317-0321)?
Weekly Report · 03/24 10:48
Weekly Report: what happened at AGYTF last week (0310-0314)?
Weekly Report · 03/17 10:57
Weekly Report: what happened at AGYTF last week (0303-0307)?
Weekly Report · 03/10 10:58
Weekly Report: what happened at AGYTF last week (0224-0228)?
Weekly Report · 03/03 10:57
More
Webull provides a variety of real-time AGYTF stock news. You can receive the latest news about Allergy Ther through multiple platforms. This information may help you make smarter investment decisions.
About AGYTF
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil, Oralvac and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.